[The use of hepatoprotector LiverPro in combined therapy of chronic viral hepatitis C].
We analysed clinical characteristics, laboratory findings, nature and frequency of side effects, and positive virologic response rate in 20 patients with chronic viral hepatitis C (HCV) given combined antiviral therapy with PEG-Intron, ribavirin, and LiverPro hepatoprotector (Santegra, USA, two capsules twice daily) during 3 months. The results were compared with those obtained in the control group of HCV patients receiving the same treatment excepting the hepatoprotector. Clinical manifestations of HCV in the former group disappeared 7-10 days earlier than in control. Also, cytolytic syndrome resolved in these patients, the positive virologic response rate was 20% higher and the frequency of severe side effects of interferon therapy that required its withdrawal was 10% lower. The authors recommend to include LiverPro in combined therapy of HCV.
Tel'nykh
Iu V
IuV
Maevskaia
M V
MV
Glushenkov
D V
DV
D000328:Adult; D000998:Antiviral Agents / Q000009:adverse effects* / Q000627:therapeutic use; D004338:Drug Combinations; D004358:Drug Therapy / Q000379:methods*; D004359:Drug Therapy, Combination; D005260:Female; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D007372:Interferons / Q000009:adverse effects* / Q000627:therapeutic use; D008099:Liver / Q000187:drug effects*; D008297:Male; D010713:Phosphatidylcholines / Q000627:therapeutic use*; D000077385:Silybin; D012838:Silymarin / Q000627:therapeutic use; D055815:Young Adult
D000998:Antiviral Agents; D004338:Drug Combinations; D010713:Phosphatidylcholines; D012838:Silymarin; D000077385:Silybin; D007372:Interferons